Acute myelogenous leukemia chemotherapy

Thioguanine is used primarily as part of induction chemotherapy regimens for acute myelogenous leukemia (AML). 

Cytarabine is used in the chemotherapy of acute myelogenous leukemia, usually in combination with anthracyclines, thioguanine, or both. It is less useful in acute lymphoblastic leukemia and lymphomas and has marginal activity against other tumors. Myelosuppres-sion is a major toxicity, as is severe bone marrow hypoplasia nausea and mucositis may also occur. 

F. Role in therapy According to Micro-medex, single-agent therapy with gem-tuzumab ozogamicin has produced remission in some patients with relapsed or refractory acute myelogenous leukemia. The selective ablation of leukemic cells with this agent is an advantage over conventional chemotherapy. 

Webb, G.F. Resonance phenomena in cell population chemotherapy models. Rocky Mountain J. Math. 1990, 20 1195-1216. Andersen, L.K., Mackey, M.C. Resonance in periodic chemotherapy a case study of acute myelogenous leukemia. J. Theor. Biol. 2001, 209 113-130. 

Following induction chemotherapy in older patients with acute myelogenous leukemia, after BMT, and before and/or after PBSCT... 

Teniposide is about 10 times more potent than etoposide in causing DNA damage in vitro and in vivo. In 21 of 733 children with acute lymphoblastic leukemia in remission, who received maintenance therapy with teniposide once or twice weekly in combination with other anticancer drugs, the risk of secondary acute myelogenous leukemia was about 12 times higher than in patients who had been treated with less intensive schedules (for example a short course of teniposide for induction chemotherapy) (149). 

Schiller GJ, Nimer SD, Territo MC, et al. Bone marrow transplantation versus high-dose cytarabine-based consohdation chemotherapy for acute myelogenous leukemia in first remission. J Chn Oncol 1992 10 41 6. 

Gale RP, Horowitz MM, Rees JKH, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996 10 13-19. 

Neutropenia—result of chemotherapy for acute myelogenous leukemia... 

Acute myelogenous leukemia t(8 21) or inv(16) translocation Good Standard chemotherapy... 

Ondansetron versus palonosetron In a randomized, open comparison of ondansetron and palonosetron in the treatment of chemotherapy-induced nausea and vomiting in 143 patients with acute myelogenous leukemia receiving high-dose cytarabine, the two drugs were equally efficacious [26 ]. The most common treatment-related adverse events were constipation and headache and 22 patients reported events that were possibly or probably related to ondansetron or palonosetron. There were no cardiac adverse events that were considered possibly or probably related to ondansetron or palonosetron. 

Atallah E, Cortes J, O Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007 110(10) 3547-51. 

---